Literature DB >> 29588247

Low conversion rate of QuantiFERON-TB Gold screening tests in patients treated with tumor necrosis factor inhibitors: A retrospective cohort study identifying an important practice gap.

Jina Chung1, Adam B Aronson2, Rithu Srikantha3, Scott A Vogelgesang4, Karolyn A Wanat5.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29588247     DOI: 10.1016/j.jaad.2018.03.025

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  5 in total

1.  Conversion Rate of Tuberculosis Screening Tests among Dermatology Patients Treated with Tumor Necrosis Factor Inhibitors.

Authors:  Sarah F Alsukait; Alaa B Alsaad; Ghadah F Alotaibi; Fahad M Alsaif; Hend M Alotaibi
Journal:  Indian J Dermatol       Date:  2022 Jan-Feb       Impact factor: 1.757

2.  The prevalence of latent tuberculosis in dermatology patients on immunosuppressant therapy in New Orleans, Louisiana: A retrospective record review.

Authors:  Erika Elliott; Rebecca Sarac; Soraya Foutouhi; Jalal Maghfour; Nayha Patel; Juliana Martel; Andrea Murina
Journal:  J Am Acad Dermatol       Date:  2019-12-20       Impact factor: 11.527

3.  Conversion and Reversion Rates of Tuberculosis Screening Assays in Patients With Rheumatic Diseases and Negative Baseline Screening Under Long-Term Biologic Treatment.

Authors:  Konstantinos Thomas; Emilia Hadziyannis; Chrisoula Hatzara; Anastasia Makris; Christina Tsalapaki; Argyro Lazarini; Kalliopi Klavdianou; Katerina Antonatou; Christos Koutsianas; Dimitrios Vassilopoulos
Journal:  Pathog Immun       Date:  2020-02-26

4.  Conversion of Tuberculosis Screening Tests During Biologic Therapy Among Veteran Patient Population With Rheumatic Disease.

Authors:  Debendra Pattanaik; Sandeep Gupta; Syed Islam; Kunal Singhal; Syed Raza
Journal:  ACR Open Rheumatol       Date:  2019-08-29

5.  The seroconversion rate of QuantiFERON-TB Gold In-Tube test in psoriatic patients receiving secukinumab and ixekizumab, the anti-interleukin-17A monoclonal antibodies.

Authors:  Chen-Yu Wu; Hsien-Yi Chiu; Tsen-Fang Tsai
Journal:  PLoS One       Date:  2019-12-27       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.